Join the AInnovation Summit at VivaTech! Explore how AI drives real business impact with Qwen, Wan, HappyHorse & HappyOyster. 📅 June 17, 15:00 CEST 📍 Paris Expo Porte de Versailles #VivaTech# #AlibabaCloud# #AInnovationSummit#

From July 14–16, Alibaba Cloud and Bosch Digital hosted AINNOVATION DAY across Shanghai, Hangzhou, and Suzhou. The event brought together over 120 participants of all backgrounds to drive enterprise Cloud and AI co-creation. We were honored to have the support of Dr. Xia Yuhu (Regional President, Bosch Digital) alongside global experts Geckle Martin, Klein Markus, and Lukaszuk Marta to provide on-site mentorship. Driven by incredible passion and imagination, teams turned raw ideas into realistic solutions in just a few hours. This sprint yielded over 40 projects covering a wide spectrum of use cases, ranging from industrial IoT and energy transition to smart home solutions like AI refrigerators and daily lifestyle hacks. The event was highly well-received, offering invaluable insights to shape our future product roadmap. Sincere thanks to all leaders, mentors and participants, for making this milestone a success! Watch the event highlights below👇 #AlibabaCloud# #Bosch# #AI#

🤖 Powerful AI empowerment workshop in Macau this week From Cantonese speech recognition to faster administrative approvals and smarter healthcare — the workshop proved that real AI value comes from solving local problems. 💪 Interested in how AI can work for your business in Macau? Let's connect: #AlibabaCloudISV# #AIforMacau# #AInnovation#

A 25-year-old scientist is taking on one of cardiology's biggest challenges: helping the heart repair itself after a heart attack. When a heart attack blocks blood flow, heart muscle cells in the affected area can die within hours. Unlike tissues such as the skin or liver, the heart has very little ability to regenerate. Instead, the damaged area is replaced with scar tissue, which can't contract like healthy muscle. Over time, this loss of function can weaken the heart and increase the risk of chronic heart failure. Pilar Ferrer, a biologist and graduate of Favaloro University in Argentina, is developing an experimental hydrogel through her startup, Amnova Biotech. Inspired by the amniotic membrane—a placental tissue already used in regenerative medicine—the gel is designed to be injected into damaged heart tissue, where it serves as a supportive scaffold that may encourage the body's own repair processes rather than leaving behind only scar tissue. So far, studies in sheep have shown encouraging results, including smaller areas of damage and improved heart function after treatment. While these findings are exciting, they're still in the early stages. Human clinical trials are not expected to begin until around 2028, and many therapies that succeed in animals ultimately fail to produce the same results in people. If future research confirms its effectiveness, this regenerative strategy could represent a major shift in how heart attack damage is treated. Would you be interested in seeing treatments that focus on rebuilding heart tissue instead of simply managing permanent scarring?

Less than a week to the Alibaba Cloud x TiDB AI Innovation Night - and seats are filling up fast! From agentic AI and AI-ready data infrastructure to real-world deployment strategies and measurable ROI, hear how enterprises are turning AI ambition into business impact. Connect with industry leaders and peers over an evening of conversations, networking, dinner, drinks, and a few surprise elements along the way. Register now: Lumen #AlibabaCloudSG# #AlibabaCloudPartner# #AlibabaCloud# #AI# #DigitalTransformation# #LLM# #Qwen# #Wan# #ContentCreation# #DigitalUpskilling# #CloudComputing# #AInnovation# #TiDB# #LingYang# #AgenticAI# #GenAI#

AI has become the new norm - are you ready for the transformation? ⚡ From visual creativity to automated workflows, AI is changing the game. We’ve captured the top AI use cases to fuel your innovation. No matter your scale, we’re here to empower your success as your trusted AI Innovation platform. Get started now—apply for free credits to explore our high-performance AI solutions! 👉 Alibaba Cloud, Your AInnovation Platform.

Smart Studio: Self-host the latest AI 🚀 Stop jumping between platforms. Everything you need to test and serve models is now in one place: ✅ Instant SOTA Access: Run Qwen3.6-Max, DeepSeek-v4, and the latest models the moment they drop. ✅ Full Multimodal Support: Access multimodal and Image & Video generation models. ✅ Visual Model Lab: Compare open vs. closed-source outputs side-by-side. ✅ HF-to-API in Minutes: Turn Hugging Face model into live API in minutes. 🔗: #AlibabaCloud# #SmartStudio# #ModelExploration# #GenAI# #AInnovation# #LLM#

I'm a cardiologist. Every day I tell patients some version of the same hard truth: the heart muscle you lost in your heart attack is gone. It won't grow back. We can open the artery, but the dead zone becomes scar — and scar doesn't beat. A 25-year-old scientist in Argentina is trying to prove me wrong. And her approach is clever enough that I'm rooting for her. Here's the problem she's attacking. When an artery blocks, heart muscle in that zone starts dying within hours. Unlike your skin or your liver, the adult human heart barely regenerates. So your body does the only thing it can — it patches the hole with fibrous scar. That scar doesn't contract. The heart pumps weaker, stretches, thins, and marches toward heart failure. This is why roughly half of heart failure patients die within five years. We manage the decline. We don't reverse it. Pilar Ferrer and her team at Amnova Biotech are going after the thing we've never solved: rebuilding the muscle itself. Their tool is inspired by one of the most quietly remarkable tissues in biology — the amniotic membrane. The sac that surrounds a baby in the womb. It's rich in regenerative and anti-inflammatory factors, and doctors already use it to heal stubborn wounds and repair the cornea. They've turned that biology into an injectable hydrogel. Cell-free — no stem cells, no animal components. It ships as a room-temperature powder, gets reconstituted, and is injected directly into the damaged heart zone, ideally during bypass surgery — the operation another Argentine, René Favaloro, gave the world. Once inside, it acts as a temporary scaffold that reengineers the healing environment: it calms the destructive inflammation, grows new blood vessels, and signals the heart's own cells to proliferate and repopulate the dead zone. Instead of surrendering to scar, the tissue gets a second chance to rebuild. The early data, in sheep — chosen because their hearts are close to ours in size and physiology — showed at 28 days: smaller infarcts, improved heart function, more new blood vessels, more dividing cardiac cells. Now the honest part, because I owe you both halves. This is early. It's preclinical. And the history of cardiology is a graveyard of therapies that looked beautiful in sheep and pigs and then failed in humans — different immune responses, different healing, different scale. Human trials aren't expected until around 2028. There is no peer-reviewed efficacy publication yet. This is a candidate to watch, not a treatment to expect. But I want to tell you why it still moves me. The whole strategy is elegant. It doesn't fight the body — it borrows the body's own oldest regenerative wisdom, the biology that builds an entire human being from scratch, and points it at a broken heart. It's cell-free, so it sidesteps the rejection and manufacturing nightmares that have stalled stem-cell approaches. It's stable at room temperature and delivered during an operation we already perform. Practical, not sci-fi. And it's the frontier I've been writing about for months, arriving from an unexpected place: the shift from managing damage to reversing it. Gene editing for cholesterol. Cell therapy for diabetes. Enzymes that erase arterial aging. And now, maybe, a gel that teaches the heart to remember how to heal. For my entire career, "the muscle is gone" has been a sentence with no appeal. A 25-year-old may be writing the appeal. Science with an Argentine accent — born in the same country that gave the world the bypass. Worth watching closely.